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1. Introduction 
Hybrid cells obtained by fusion of rat glioma and 
mouse neuroblastoma cells display many properties 
characteristic of differentiated neurons [ 1,2] . On 
treatment with N6 -2’0dibutyryl adenosine -3’: 5’- 
cyclic monophosphate (dibutyryl cyclic AMP) they 
extend long processes [l-4] . In containing choline 
acetyltransferase of high specific activity [ 1,2,5,6] 
and dopamine-/3-hydroxylase [3] they have marker 
enzymes of both cholinergic and adrenergic nerves. 
They fire action potentials on electrical stimulation or 
when acetylcholine is applied to their plasma 
membrane. The response to acetylcholine can be 
blocked by the cholinergic antagonists d-tubocurarine, 
atropin or cr-bungarotoxin [ 1,2] . When exposed to 
prostaglandin El, neuroblastoma [7,8] and hybrid 
cells [9] increase their intracellular concentration of 
cyclic AMP. In both cell types this effect can be 
antagonized by morphine [lo] . The basal level of 
cyclic AMP in unstimulated cells or the elevated level 
in cells exposed to a phosphodiesterase inhibitor is 
lowered in the presence of noradrenaline (NA) [9]. 
In extension of this work we now report that in the 
hybrid cells NA at low concentrations also prevents 
the increase of intracellular levels of cyclic AMP evoked 
by PGEi . In doing so it is a more potent agent than 
dopamine, phenylephrine and isoproterenol (order of 
decreasing potency). The adrenergic a-blocker 
phentolamine antagonizes the action of NA more 
effectively than the I(-blocker propranolol. The data 
suggest he adrenergic receptor to be classified as 
a-receptor [ 111. Also opiates, in a highly stereospecific 
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way, and cholinergic agonists [ 121 antagonize the 
action of PGEr on the hybrid cells. In view of the 
membrane depolarizing action of acetylcholine and of 
the comparable behavior of NA, morphine and 
acetylcholine in antagonizing the action of PGEr on 
the levels of cyclic AMP, the effect of morphine, NA 
and PGEi on the membrane potential of the hybrid 
cells was tested. As expected, morphine and NA (like 
acetylcholine) depolarize, whereas PGEi hyperpolarizes 
the plasma membrane. 
2. Methods 
2.1. C%emicals 
Lnoradrenaline hydrochloride and D, Lpropranolol 
hydrochloride were purchased from Sigma, dopamine. 
HCl and D, Lisoproterenol.HCl from Serva, Lphenyl- 
ephrine.HCl from C. Roth and morphine.HCl from 
Boehringer, Ingelheim. Phentolamine.HCl was a gift 
from Ciba-Geigy; haloperidol from Janssen Pharma- 
ceutica, levorphanol and dextrorphan from Hoffmann- 
La Roche and Professor A. Herz, isobutylmethyl- 
xanthine from Searle and Co. and prostaglandins from 
Dr J. Pike, The Upjohn Co. 
2.2. Cell culture and experimental incubation 
Line N4TG3 is a 6-thioguanine resistent mutant [6] 
of line N4 [ 13 3 derived from mouse neuroblastoma 
C-l 300. 108CC5 and 108CC1.5 are clonal mouse 
neuroblastoma X rat glioma hybrid lines [ 1,2] . Clone 
108CC25 was obtained after fusion of 108CC5 cells 
with each other [I 41. The cells were cultured in 
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surface of the medium, from were they had to diffuse 
down to the impaled cell. Details will be given 
elsewhere [ 171. 
3. Results and discussion 
When hybrid cells 108CC1.5 are exposed to PGEr , 
the intracellular level of cyclic AMP increases strongly. 
The effect is antagonized by levorphanol (fig.1, curve I), 
a congener of morphine, but not by dextrorphan, the 
biologically inactive enantiomer of levorphanol (fig.1, 
curve II). This result demonstrates the stereospecificity 
Fig.1. Formation of cyclic AMP in the presence of 3 PM 
PGE, and varying concentrations of levorphanol (I) or 
dextrorphan (II). The control values in the absence of PGE, 
are between 9.6 and 13.1 pmol cyclic AMP/mg protein. 
Replica plates; 1.6 X lo* 108CC15 cells per plate; viability 
90%; passage number 18. 
plastic petri dishes 8.5 cm in diameter (Greiner, 
Ntirtingen) [9]. 
Experimental incubations in the presence of various 
drugs were for 10 min at 37°C as described [ 151. 
Isolation and quantitation of cyclic AMP were done as 
reported [15] . Cells of clones 108CC5, 108CC15 and 
108CC25 were stimulated to extend processes 
(differentiated hybrid cells) by culturing in medium 
containing 1 mM dibutyryl cyclic AMP [l-3] . 
2.3. Electrophysiologv 
Intracellular recording from and stimulation of 
single differentiated cells was via glass electrodes filled 
with 3 M KCl. Drugs were applied to the cells in one 
of two ways. They were either iontophoretically 
released from micropipettes to the surface of the cells, 
or they were added as concentrated solutions to the 
)- 
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Fig.2. Formation of cyclic AMP in the presence of 3 WM 
PGE, and varying concentrations of NA (I), phenylephrine 
(II), dopamine (III) and isoproterenol (IV). The control 
values in the absence of PGE, are between 5.5 and 8.6 pmol 
cyclic AMP/mg protein. Replica plates; 2 X lo* 108CClS 
cells per plate; viability 91%; passage number 6. 
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Table 1 
Effect of adrenerglc agonists and antagonists on the intracelullar levels of cyclic AMP (pmol/mg protein) 
in hybrid cell line 108CC15 stimulated by PGE, . 
Agonist 
Antagonist Concen- 
tration 
(/JM) 
None L-NA (10 PM) Dopamine (10 MM) D,L-isoproterenol 
(20 rcM) 
None _ 1210 f 70 151 f 35 228 + 24 488 f 40 
Phentolamlne 10 - 543 f 46 1040 f 70 1040 f 80 
100 1350 f 30 957 f 61 1040 f 90 1040 ?: 70 
Haloperldol 10 1440 165*12 395 f 27 665 * 46 
100 - 340 + 40 765 f 35 1290 + 20 
Propranolol 10 - 176 i 18 298 * 32 817 + 73 
100 1630 f 24 237 + 33 643 i 133 1230 + 100 
Data (+ standard deviations) are mean values obtained with 3 plates. All incubations were in the presence of 
3 PM PCE, and combinations of agonists and antagonists. 1.5 X lo6 viable cells per plate; viability 98%; 
passage number 10. The control values (pmol cyclic AMP/mg protein) found in the absence of PGE, are: 
no additions 12; 10 PM NA 13; 10 WM dopamine 22; 200 WM D,L-isoproterenol 19; 100 WM phentolamine 17; 
100 PM haloperidol 12; 200 PM D,Gpropranolol 11. 
Table 2 
Effects of PGE, , morphine, NA and IBMX and some combinations of these compounds 
on the intracellular levels of cyclic AMP (pmol/mg protein) in neuroblastoma nd hybrid 
cells. The values given without standard deviations were obtained from incubation of 
single plates. In the cases in which 2 concentrations are given, they refer to the first and 
second compound, respectively, that had been added to the incubation medium. 
Addition Concentration (MM) Cell line 
N4TG3 108CC15 108CC25 
None _ 6 10 16 
PGE, 3 122 811 f 109 116+- 16 
NA 100 5 14+ 0 9*3 
IBMX 500 - 41 42 
Morphine 10 _ _ 15 
Morphine 100 - - 8 
PGE, + NA 
PGE, + morphine 
PGE, + morphine 
PGE, + IBMX 
NA + IBMX 
3100 45 12Ok 7 45 f 1 
3100 - - 90 
3100 _ - 106 
3500 - - 1233 
100 500 _ _ 24 
Viable cells per plate 
x 1o-s 
Viability % 
Protein per plate (mg) 
8 1.6 0.8 
- 90 94 
7 3.1 1.8 
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of the opiate action on the hybrid cells and is in 
agreement with similar findings on PGEr -stimulated 
adenyl cyclase [ 181, with stereospecific opiate binding 
in brain homogenates [ 1992 1 ] , synaptic plasma 
membranes from brain [22 ] , intact neuroblastoma 
cells [23] and homogenates of neuroblastoma X glioma 
hybrid cells [24] . 
If in an experiment analogous to the one discussed 
the opiate is substituted by NA, qualitatively the same 
phenomenon is observed. The increase in the 
intracellular concentration of cyclic AMP due to the 
activity of PGEr is strongly inhibited (fig.2). The 
susceptibility of the cells to aromatic amines decreases 
in the sequence NA, (curve I, concentration at which 
50% inhibition occurs, IC50:0.05 PM) dopamine 
(curve III, IC50:0.5 PM), isoproterenol (curve IV, 
IC50:5 MM). The response to phenylephrine (curve II, 
IC50: 1.2 FM) appears to be biphasic. The fact that the 
sensitivity of the cells to NA is much higher than that 
to isoproterenol, suggests the presence of adrenergic 
o-receptors rather than P-receptors. This view is 
supported by the results shown in table 1. The 
responses to NA, dopamine or isoproterenol are much 
more strongly inhibited by the adrenergic a-blocker 
phentolamine than by the dopamine antagonist 
haloperidol or the P-blocker propranolol. Interestingly, 
propranolol and haloperidol are more powerful in 
blocking the actions of dopamine or isoproterenol 
than of NA. 
NA antagonizes the effect of PGEr also in the 
neuroblastoma line N4TG3 and the hybrid line 
108CC25 (table 2). The latter cells are only slightly 
sensitive to morphine. The phosphodiesterase inhibitor 
IBMX elevates the level of cyclic AMP in line 108CC25. 
The effect is partially inhibited by NA. A similar 
phenomenon had been observed with lines 108CC5 
and 108CC15 [9] . This result indicates that the 
depression of accumulation of cyclic AMP in the 
presence of NA is not due to an increase in 
phosphodiesterase activity, but rather to reduced 
adenylate cyclase activity. Since morphine, acetyl- 
choline and NA stimulate the levels of intracellular 
guanosine 3’: 5’cyclic monophosphate (cyclic GMP) 
in neuroblastoma and hybrid cells [25], our working 
hypothesis is that the depression of formation of 
cyclic AMP by these compounds is mediated by cyclic 
GMP. 
The hybrid cells stimulated by PGEr to high levels 
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of cyclic AMP can be screened for hormone receptors 
controlling guanylate cyclase activity. Usually the 
ratio of the level of cyclic nucleotide in stimulated to 
that in unstimulated cells is higher for cyclic AMP 
than for cyclic GMP. Therefore, the depression of 
cellular cyclic AMP concentrations, in the presence of 
hormonally elevated levels of cyclic GMP, provides a 
more sensitive assay for the action of these hormones 
than measuring cyclic GMP levels directly. For assessing 
extracellular influences mediated by intracellular cyclic 
GMP this approach could be useful with other cells, 
too, provided there are hormones that cause a strong 
increase in the levels of cyclic AMP. Our previous 
findings [9] and the present communication are the 
first reports of a cyclic AMP depressing action of NA 
or related compounds on neuroblastoma and their 
hybrid cells. Pmvious workers had found no influence 
of 0.1 mM isoproterenol or dopamine on levels of 
cyclic AMP in mouse neuroblastoma cells [26] , or 
dopamine was observed to stimulate (rather than 
inhibit) adenylate cyclase in homogenates of mouse 
neuroblastoma cells more effectively than NA [27]. 
These differences in the results on neuroblastoma 
cells might be due to the use of different clones, albeit 
of the same tumor. A relationship between PGEr 
(causing increase of cellular cyclic AMP) and NA 
(causing increase of cyclic GMP and decrease of cyclic 
AMP) that is completely analogous to the one reported 
here, has been observed in human platelets [28]. In 
the ductus deferens of the rat, NA slightly increases 
the level of cyclic GMP. However, in contrast to our 
findings, NA does not lower the level of cyclic AMP 
[29]. In rat pituitary glands the accumulation of cyclic 
AMP evoked by PGEs is depressed in the presence of 
somatostatin [30]. This suggests that the action of 
somatostatin is mediated by cyclic GMP. There are a 
number of examples in which prostaglandins behave 
as antagonists of NA or other hormones, although 
with exchanged roles. The elevation of intracellular 
cyclic AMP by NA or other hormones is inhibited by 
PGEr [31-351. An antagonism between PGE and NA 
at synapses has been found in vas deferens [36,37] 
and at cerebellar Purkinje cells [38]. At the present it 
is not clear whether the systems are comparable at all 
[39] and to what extent our findings are related to 
the ones obtained with these two tissues. 
In order to assess the effects on membrane 
potentials of the compounds influencing levels of 
0 5 set 10 
Fig.3. Influence of PGE, , morphine and NA on the membrane 
potential of hybrid cells 108CC15 treated with dibutyryl 
cyclic AMP. A) Influence of PGE, . At the time indicated 
(arrow) 2 ~1 of 1 mM PGE, were added to the surface of the 
medium above the cell. 5 cells were tested, yielding the same 
result. B) Influence of morphine. Same cells as in A. 2 ~1 
10 mM morphine was added (arrow). 31 cells were tested with 
identical results. C) Influence of NA applied iontophoretically 
from micropipettes fiied with 0.1 M NA.HCl in 0.1 M HCl. 
Iontophoretic application of 0.1 M HCl or NaCl was without 
effect. A total of 11 cells was tested, showing the same 
result. 
In different preparations of nerve, muscle or brown 
fat cells PGEl is known to depolarize [38,41,42] , 
hyperpolarize [43], first hyper- then depolarize [44], 
or not influence resting membrane potentials [45]. 
In two of the systems, NA and PGEl antagonize each 
other [38-431, one [43] showing responses to PGEl 
and NA like our hybrid cells do. Morphine excited or 
inhibited various nerve cells in the brain stem [46] , 
but showed only an excitatory effect on Renshaw 
cells [47]. An antagonism between PGEl and morphine 
in the action on small intestine is well documented. 
The contraction stimulated by PGEl is inhibited by 
morphine [48,49]. 
The present investigation suggests a relationship 
between the effects of neurohormones on cellular 
levels of cyclic nucleotides and on membrane potential, 
i.e. ion permeability of the plasma membrane. PGEl 
causes hyperpolarization and an increase of the level 
of cyclic AMP; acetylcholine [ 121, NA and morphine 
evoke depolarizations and depression of elevated 
levels of cyclic AMP, possibly mediated by cyclic 
GMP [25]. The common action of the latter three 
agents suggests as a primary event, the increase of the 
permeability of the plasma membrane for the same ion. 
Work is in progress to elucidate this aspect. 
cyclic AMP, hybrid cells treated with dibutyryl cyclic 
AMP were impaled with a microelectrode. Addition 
of a solution of PGEl to the medium above the cell 
evokes a slow and transient hyperpolarization of 
maximally 10 mV (fig3A), which lasts about 10 sec. 
Sometimes it is followed by a less pronounced slow 
depolarization of l-3 mV. Also PGFl (Y, but not PGAl , 
causes a slight hyperpolarization. On the other hand, 
addition of morphine is followed by pronounced 
depolarization (fig.3B), which lasts up to several 
minutes. The high rate of depolarization allows the 
development of an action potential followed by 
oscillation of the membrane potential. After the mem- 
brane potential has returned to its original value, the 
cells do no longer tire action potentials on electrical 
stimulation, in contrast to their behavior before the 
addition of morphine. However, if the plasma membrane 
is hyperpolarized electrically prior to electrical stimula- 
tion, the cells fire action potentials again. Membrane 
depolarizations by catecholamines of hybrid cells 
108CClS were also observed by others [40] . 
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A similar depolarizing effect was caused when NA 
was pipetted to the medium above the cell tested. 
Iontophoretic application of NA resulted in a 
comparatively fast depolarization, which was rapid 
enough to evoke action potentials (fig3C). Similar 
effects were obtained with dopamine. 
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